Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Gains from Investment Securities (2023 - 2025)

Immunome (IMNM) has disclosed Gains from Investment Securities for 3 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to $5.6 million, compared with a TTM value of $5.6 million through Dec 2025, up 130.44%, and an annual FY2025 reading of $5.6 million, changed N/A over the prior year.
  • Gains from Investment Securities was $5.6 million for Q4 2025 at Immunome, up from $891000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.6 million in Q4 2025 and bottomed at -$1.3 million in Q2 2024.
  • Average Gains from Investment Securities over 3 years is $1.7 million, with a median of $1.1 million recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 5166.42% in 2024, while the deepest fall reached 1434.81% in 2024.
  • Year by year, Gains from Investment Securities stood at $1.2 million in 2023, then soared by 322.24% to $5.2 million in 2024, then grew by 7.55% to $5.6 million in 2025.
  • Business Quant data shows Gains from Investment Securities for IMNM at $5.6 million in Q4 2025, $891000.0 in Q3 2025, and $224000.0 in Q1 2025.